

# Clinical evaluation of dried blood spots obtained from a fingerprick for the determination of tamoxifen and endoxifen levels

No registrations found.

<b>Ethical review</b>	Positive opinion
<b>Status</b>	Recruiting
<b>Health condition type</b>	-
<b>Study type</b>	Observational non invasive

## Summary

### ID

NL-OMON26648

### Source

NTR

### Health condition

breast cancer, estrogen receptor positive

## Sponsors and support

**Primary sponsor:** none

**Source(s) of monetary or material Support:** Bioanalytical Laboratory of Slotervaarthospital

## Intervention

## Outcome measures

### Primary outcome

Ratio between endoxifen serum concentrations and endoxifen dried blood spot concentrations

## Secondary outcome

N/A

## Study description

### Background summary

DBS samples to determine the pharmacokinetics of tamoxifen in a 'real life' cohort will be collected during a routine visit to the Antoni van Leeuwenhoek hospital where a serum sample is obtained as part of clinical care.

No relationship between DBS and serum concentrations has been established yet for tamoxifen and endoxifen. This would enable sample collection by means of a simple fingerprick. The DBS to serum ratio of tamoxifen and endoxifen has to be defined in simultaneously drawn DBS and serum samples of patients using tamoxifen.

### Study objective

Tamoxifen and endoxifen serum concentrations are linearly related to DBS concentration

### Study design

1 timepoint; a paired sample will be obtained a serum sample and a dried blood spot sample

### Intervention

Patients are treated with tamoxifen on a dose according to the prescription of the physician. No further intervention is needed. A DBS sample will be obtained simultaneously with the serum sample that is obtained for regular clinical care.

## Contacts

### Public

P.O. Box 22660

N.G.L. Jager  
Amsterdam 1100 DD

The Netherlands  
020-5663473  
**Scientific**  
P.O. Box 22660

N.G.L. Jager  
Amsterdam 1100 DD  
The Netherlands  
020-5663473

## Eligibility criteria

### Inclusion criteria

1. Treated with tamoxifen;
2. Age minimum 18 years;
3. Able and willing to give written informed consent;
4. Able and willing to undergo a fingerprick voor dried blood spot sampling.

### Exclusion criteria

None

## Study design

### Design

Study type:	Observational non invasive
Intervention model:	Parallel
Allocation:	Non controlled trial
Masking:	Open (masking not used)

Control: N/A , unknown

## Recruitment

NL  
Recruitment status: Recruiting  
Start date (anticipated): 18-03-2013  
Enrollment: 50  
Type: Anticipated

## Ethics review

Positive opinion  
Date: 21-06-2013  
Application type: First submission

## Study registrations

### Followed up by the following (possibly more current) registration

ID: 37023  
Bron: ToetsingOnline  
Titel:

### Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register	ID
NTR-new	NL3881
NTR-old	NTR4042
CCMO	NL41454.031.12
ISRCTN	ISRCTN wordt niet meer aangevraagd.
OMON	NL-OMON37023

# Study results

## Summary results

N/A